An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Acronyms LEAP
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2015 Planned End Date changed from 1 Mar 2020 to 1 Feb 2016 as reported by ClinicalTrials.gov.